Small Molecules

08 Nov 2018 Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases
07 Nov 2018 BerGenBio Reports ~80% Improvement in PFS of AXL-positive vs AXL-negative NSCLC Patients in Bemcentinib + KEYTRUDA PhII Combination Trial
07 Nov 2018 Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
07 Nov 2018 BeiGene Initiates Global Head-to-Head Phase 3 Clinical Trial of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
06 Nov 2018 Concert Pharmaceuticals Presents Preclinical Data on CTP-692, a Novel Drug Candidate for Schizophrenia, Supporting Potential to Improve Safety Profile of D-Serine
06 Nov 2018 AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
06 Nov 2018 FDA Approves Lixte Biotechnology’s IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center
06 Nov 2018 First patient dosed in Phase 2 Alpha-1 Antitrypsin Deficiency Study
05 Nov 2018 Genkyotex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
05 Nov 2018 Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNATM, a First-In-Class DNA Damage Response Inhibitor
05 Nov 2018 FLX Bio Announces Clinical Trial Collaboration Agreement With Merck for Ongoing Phase 1/2 Study of FLX475
05 Nov 2018 Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation
05 Nov 2018 Oxurion and Beta Therapeutics to Develop New Heparanase Inhibitors for Treatment of dry AMD
05 Nov 2018 Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer
05 Nov 2018 Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
05 Nov 2018 Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
05 Nov 2018 Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
05 Nov 2018 CohBar Provides Update on CB4211 Clinical Trial
03 Nov 2018 U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
02 Nov 2018 Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
01 Nov 2018 Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA
01 Nov 2018 AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
01 Nov 2018 Phase III Data Showed That Venclexta Plus Gazyva Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities
01 Nov 2018 Ark Biosciences Reports Significant Progress of Phase 2 Clinical Trial of Ziresovir for Treatment of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients
01 Nov 2018 Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up